Your browser doesn't support javascript.
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
Moyo-Gwete, Thandeka; Madzivhandila, Mashudu; Makhado, Zanele; Ayres, Frances; Mhlanga, Donald; Oosthuysen, Brent; Lambson, Bronwen E; Kgagudi, Prudence; Tegally, Houriiyah; Iranzadeh, Arash; Doolabh, Deelan; Tyers, Lynn; Chinhoyi, Lionel R; Mennen, Mathilda; Skelem, Sango; Marais, Gert; Wibmer, Constantinos K; Bhiman, Jinal N; Ueckermann, Veronica; Rossouw, Theresa; Boswell, Michael; de Oliveira, Tulio; Williamson, Carolyn; Burgers, Wendy A; Ntusi, Ntobeko; Morris, Lynn; Moore, Penny L.
  • Moyo-Gwete T; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Madzivhandila M; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Makhado Z; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Ayres F; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Mhlanga D; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Oosthuysen B; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Lambson BE; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Kgagudi P; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Tegally H; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Iranzadeh A; University of Cape Town, Cape Town, South Africa.
  • Doolabh D; University of Cape Town, Cape Town, South Africa.
  • Tyers L; University of Cape Town, Cape Town, South Africa.
  • Chinhoyi LR; University of Cape Town, Cape Town, South Africa.
  • Mennen M; University of Cape Town, Cape Town, South Africa.
  • Skelem S; University of Cape Town, Cape Town, South Africa.
  • Marais G; University of Cape Town, Cape Town, South Africa.
  • Wibmer CK; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Bhiman JN; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • Ueckermann V; Steve Biko Academic Hospital, Pretoria, South Africa.
  • Rossouw T; University of Pretoria, Pretoria, South Africa.
  • Boswell M; Steve Biko Academic Hospital, Pretoria, South Africa.
  • de Oliveira T; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Williamson C; University of Cape Town, Cape Town, South Africa.
  • Burgers WA; University of Cape Town, Cape Town, South Africa.
  • Ntusi N; University of Cape Town, Cape Town, South Africa.
  • Morris L; National Institute for Communicable Diseases, Johannesburg, South Africa pennym@nicd.ac.za.
  • Moore PL; National Institute for Communicable Diseases, Johannesburg, South Africa pennym@nicd.ac.za.
N Engl J Med ; 384(22): 2161-2163, 2021 06 03.
Article in English | MEDLINE | ID: covidwho-1170983
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: N Engl J Med Year: 2021 Document Type: Article Affiliation country: NEJMc2104192

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: N Engl J Med Year: 2021 Document Type: Article Affiliation country: NEJMc2104192